Orally active insulin mimics: where do we stand now?

Area of Science:

• Biochemistry
• Pharmacology
• Endocrinology

Background:

• Diabetes mellitus presents a growing global health challenge, particularly in developing nations.
• The increasing prevalence and complications of diabetes necessitate novel therapeutic strategies.
• The insulin receptor (IR) has been identified as a key drug target due to its critical role in glucose metabolism.

Purpose of the Study:

• To review recent advancements in the development of new anti-diabetic drugs.
• To summarize the progress in identifying and targeting the insulin receptor (IR).
• To highlight the current status of orally active insulin mimetics for type 2 diabetes.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of studies focusing on insulin receptor (IR) function and drug development.
• Evaluation of research on orally active insulin mimetics.

Main Results:

• The insulin receptor (IR) is a promising target for diabetes drug development.
• Significant research efforts are directed towards understanding IR kinase activity and molecular cloning.
• Progress has been made in developing orally active insulin mimetics.

Conclusions:

• Targeting the insulin receptor (IR) offers a viable strategy for novel diabetes therapies.
• Orally active insulin mimetics represent a promising avenue for type 2 diabetes treatment.
• Continued research is essential to accelerate the availability of new diabetes drugs.